Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

Role of radiotherapy in refractory/relapsed classical Hodgkin lymphoma in the era of targeted therapies and immunotherapy.

Clinical and translational radiation oncology·2026
Same author

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Haematology·2026
Same author

Outcomes of critically ill patients with newly diagnosed Burkitt's lymphoma: a monocentric retrospective study.

Annals of intensive care·2026
Same author

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Second-line treatment paradigms for diffuse large B-cell lymphomas.

Catherine Thieblemont1, Christian Gisselbrecht

  • 1Hôpital Saint Louis, Hemato-Oncologie, Institut Universitaire d'Hématologie, 1 Avenue Claude Vellefaux, 75010 Paris, France.

Current Oncology Reports
|August 15, 2009
PubMed
Summary
This summary is machine-generated.

Despite advances in diffuse large B-cell lymphoma treatment, many patients relapse. This review examines optimal salvage chemotherapy, rituximab efficacy, and emerging biologic therapies for relapsed or refractory disease.

Related Experiment Videos

Last Updated: Jun 21, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

  • Oncology
  • Hematology
  • Immunotherapy

Background:

  • Diffuse large B-cell lymphoma (DLBCL) treatment advances include dose-intense regimens and rituximab.
  • A significant proportion of DLBCL patients experience treatment failure, partial response, or relapse.
  • Standard salvage for chemosensitive relapses involves chemotherapy followed by high-dose therapy and autologous stem cell transplantation.

Purpose of the Study:

  • To address critical questions regarding optimal salvage regimens for relapsed DLBCL.
  • To evaluate the efficacy of rituximab in the context of R-CHOP standard frontline therapy.
  • To identify risk factors in second-line therapy and explore alternatives when transplantation is not feasible.

Main Methods:

  • Review of existing literature on DLBCL salvage therapy.
  • Analysis of rituximab's role in relapsed/refractory DLBCL.
  • Discussion of novel biologic therapies and prognostic biomarkers.

Main Results:

  • The optimal salvage regimen for DLBCL remains an area of active investigation.
  • Rituximab's efficacy in relapsed settings requires further clarification.
  • Understanding biologic parameters is key to improving outcomes in patients with poor prognosis.

Conclusions:

  • Further research is needed to define the best salvage strategies for DLBCL.
  • New biologic therapies hold promise for improving outcomes in relapsed/refractory DLBCL.
  • Personalized treatment approaches based on biologic understanding are crucial for optimizing patient care.